Central Precocious Puberty in a Toddler
A 20-month-old boy is referred to a paediatric endocrine clinic for evaluation.
A 20-month-old boy is referred to a paediatric endocrine clinic for evaluation.

The Endocrine Society has published a clinical practice guideline on the diagnosis and treatment of children with central precocious puberty in The Journal of Clinical Endocrinology & Metabolism.

International guidance has been published on managing the transition of children with endocrine disorders from paediatric to adult services, and on the use of genetic testing in children with short stature.

UK study findings indicate that a slow-release formulation of the gonadotropin-releasing hormone analogue triporelin given every 24 weeks is as effective as the standard 12-weekly treatment for central precocious puberty.
For teenage boys with idiopathic short stature (ISS), combining a third-generation aromatase inhibitor with recombinant human growth hormone therapy can significantly improve adult height, suggest study findings published in the Journal of Clinical Endocrinology & Metabolism.

Study findings demonstrate the broad heterogeneous phenotypes found in children with 46,XY gonadal dysgenesis, with insights into likelihood of spontaneous puberty and risk of gonadal malignancy.
Measuring levels of testosterone, inhibin B and anti-Müllerian hormone at different time points over the first year of life may help diagnose congenital hypogonadotropic hypogonadism in infant boys with minor abnormalities of the external genitalia, French researchers say.
Children and adolescents with congenital adrenal hyperplasia
appear to have impaired psychosocial quality of life, particularly in the school domain, while physical QoL is preserved, suggest findings of a systematic review and meta-analysis.

Research has demonstrated a dose–response relationship between the number of supernumerary X chromosomes in young people with high-grade aneuploidies and the level of endocrine system impairment experienced.
Gonadotropin-releasing hormone analogue therapy offers a similar benefit to girls with early fast puberty as it does to those with central precocious puberty, the results of an observational study suggest.